Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
Key Highlights
- ➤PHIO will present final Phase 1b PH-762 clinical data at the 41st Annual SITC Meeting
- ➤Phase 1b evaluated intratumoral PH-762 as a neoadjuvant treatment for cutaneous carcinomas
- ➤Study findings suggest PH-762 was well-tolerated and may spare tissue versus standard surgery
- ➤Phio plans a Phase 2b PH-762 study in the first half of 2027
Expert Statements
Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals
“The growing body of clinical evidence suggests that PH-762 may offer patients and physicians a meaningful new treatment option capable of shrinking tumors prior to surgery while maintaining an attractive safety profile.”
Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals
“We believe these findings support PH-762's potential to become a differentiated, tissue-sparing neoadjuvant treatment that may reduce the burden of surgery while preserving favorable clinical outcomes.”
INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL(®) gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Phoenix, Arizona from November 6-8, 2026.
Get started
Create a free account to read the full story.